Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Terns Pharmaceuticals Inc (TERN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: TERN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $20
1 Year Target Price $20
| 5 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 9.78% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 618.70M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 9 | Beta -0.06 | 52 Weeks Range 1.86 - 11.40 | Updated Date 08/29/2025 |
52 Weeks Range 1.86 - 11.40 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.03 |
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.2918 | Actual -0.26 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.97% | Return on Equity (TTM) -35.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 304391109 | Price to Sales(TTM) 302.64 |
Enterprise Value 304391109 | Price to Sales(TTM) 302.64 | ||
Enterprise Value to Revenue 337.47 | Enterprise Value to EBITDA -5.8 | Shares Outstanding 87511000 | Shares Floating 57156091 |
Shares Outstanding 87511000 | Shares Floating 57156091 | ||
Percent Insiders 0.3 | Percent Institutions 99.08 |
Upturn AI SWOT
Terns Pharmaceuticals Inc
Company Overview
History and Background
Terns Pharmaceuticals Inc. is a global biopharmaceutical company founded in 2016. It focuses on developing treatments for chronic liver diseases, including non-alcoholic steatohepatitis (NASH) and other diseases.
Core Business Areas
- NASH Programs: Terns' primary focus is developing treatments for NASH, including small molecule and combination therapies.
- Oncology Programs: Terns is also exploring therapeutics in the oncology space.
Leadership and Structure
Terns is led by a management team with experience in drug development and commercialization. The organizational structure is typical of a biopharmaceutical company, with research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- TERN-501: A thyroid hormone receptor beta (THR-u03b2) agonist for NASH. It is currently in clinical development. Competing THR-u03b2 agonists include Viking Therapeutics' VK2809 (VKTX) and Madrigal Pharmaceuticals' Resmetirom (MDGL).
- TERN-601: An oral GLP-1 receptor agonist for NASH. It is also in clinical development. Competitors include Novo Nordisk's semaglutide (Ozempic, Wegovy) and Eli Lilly's tirzepatide (Mounjaro, Zepbound).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. The NASH market is a large and growing market with significant unmet medical need.
Positioning
Terns aims to be a leader in developing treatments for NASH. Its competitive advantage lies in its portfolio of differentiated drug candidates.
Total Addressable Market (TAM)
The global NASH market is expected to reach tens of billions of dollars in the coming years. Terns is positioned to capture a share of this market with successful clinical development and commercialization.
Upturn SWOT Analysis
Strengths
- Strong scientific team
- Differentiated drug candidates
- Focus on a large and growing market
- Pipeline in development
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial success
- Competition from established players
- No currently marketed products
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new indications
- Accelerated regulatory approval
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from new entrants
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MDGL
- GILD
- NVO
- LLY
- VKTX
Competitive Landscape
Terns faces significant competition from established pharmaceutical companies with greater resources and experience. Its competitive advantage lies in its differentiated drug candidates and focus on the NASH market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's development stage. Growth is expected to accelerate upon successful commercialization of its drug candidates.
Future Projections: Future growth is dependent on clinical trial outcomes and regulatory approvals. Analyst estimates vary widely depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing its NASH programs through clinical trials and exploring partnerships for its drug candidates.
Summary
Terns Pharmaceuticals is a development-stage company focused on NASH treatments. Its success hinges on positive clinical trial results and securing partnerships. The company faces significant competition and financial risks, but its differentiated drug candidates offer potential for growth. The company has no products on the market and is pre-revenue. Investors should closely monitor clinical trial progress and cash burn.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Company press releases
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be complete or accurate. Investment decisions should be based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Terns Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 2021-02-05 | CEO & Director Ms. Amy L. Burroughs M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://www.ternspharma.com |
Full time employees 59 | Website https://www.ternspharma.com | ||
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.